9 episodes
On Point BioMérieux
-
- Science
Infectious diseases like respiratory infections and gastroenteritis can be difficult to diagnose at the point of care due to similar, overlapping symptoms. Join seasoned physicians as they discuss how the syndromic approach—simultaneously testing for several pathogens associated with a disease syndrome—can offer fast, comprehensive answers at the point of care, helping get patients on the right treatment sooner.
-
Dr. Connor Describes How the BIOFIRE GI Panel May Impact Treatment and Patient Satisfaction
Tune in as Dr. Brad Connor describes how the BIOFIRE® FILMARRAY® Gastrointestinal Panel helped facilitate appropriate treatment for a pediatric patient, as well as the benefit of having testing available directly on-site* and how the test may improve patient satisfaction.
Dr. Connor received an honorarium from bioMérieux for his participation in this podcast.
Learn more here: https://www.biofiredx.com/
*The BIOFIRE GI Panel is intended to be run on the BIOFIRE® FILMARRAY® TORCH and the BIOFIRE® FILMARRAY® 2.0 in CLIA-moderate settings. -
Dr. Connor Shows How the Comprehensive BIOFIRE GI Panel Helps Provide Diagnostic Certainty
In this episode, Dr. Brad Connor uses a case study from a returning traveler to illustrate how the BIOFIRE® FILMARRAY® Gastrointestinal Panel helps provide diagnostic certainty by identifying a broad grouping bacteria, viruses, and parasites.
Dr. Connor received an honorarium from bioMérieux for his participation in this podcast.
More about the power of PCR diagnostic testing in point-of-care clinics here. -
Gastroenterologist Dr. Bradley Connor on the value of outpatient syndromic testing.
Join Dr. Brad Connor, a gastroenterologist with a specialty in travel tropical medicine and infectious diseases, as he talks with Connie Zellner, medical education liaison with bioMérieux, about his decision to adopt the BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel and how it has helped him in his gastroenterology clinic.
Dr. Connor received an honorarium from bioMérieux for his participation in this podcast.
More about the power of PCR diagnostic testing in point-of-care clinics here. -
Dr. Smith on Syndromic Testing and Patient Satisfaction
In this episode, Dr. Smith explores a case study where he utilized the BIOFIRE® Respiratory Panel to help identify whether a pediatric patient had an exacerbation of allergic rhinitis or a respiratory infection. He wraps up by showing how BIOFIRE respiratory solutions have helped improve patient satisfaction.
This podcast was sponsored by bioMerieux.
More about the power of PCR diagnostic testing in point-of-care clinics here.
This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. -
Dr. Smith Uses Case Studies to Discuss Diagnostic Certainty
In this episode, Dr. Smith delves into two case studies, including one patient with cold urticaria and one with a history of asthma, and describes how the comprehensive BIOFIRE® Respiratory Panel gave him the diagnostic certainty to provide the correct treatment to his patients.
This podcast was sponsored by bioMerieux.
More about the power of PCR diagnostic testing in point-of-care clinics here.
This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. -
Asthma, Allergy and Immunologist Dr. Smith on BIOFIRE Multiplex PCR Testing
Join Dr. Christopher Smith as he talks with Connie Zellner, Medical Education Liaison with bioMérieux, about his decision to adopt the BIOFIRE multiplex respiratory panel and how it has helped him in his asthma and allergy clinic.
This podcast was sponsored by bioMerieux.
More about the power of PCR diagnostic testing in point-of-care clinics here.
This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.